Advertisement

Molecular Medicine

, Volume 19, Issue 1, pp 357–366 | Cite as

Emerging Role of High-Mobility Group Box 1 (HMGB1) in Liver Diseases

  • Ruochan Chen
  • Wen Hou
  • Qiuhong Zhang
  • Rui Kang
  • Xue-Gong Fan
  • Daolin Tang
Review Article

Abstract

Damage-associated molecular pattern (DAMP) molecules are essential for the initiation of innate inflammatory responses to infection and injury. The prototypic DAMP molecule, high-mobility group box 1 (HMGB1), is an abundant architectural chromosomal protein that has location-specific biological functions: within the nucleus as a DNA chaperone, within the cytosol to sustain autophagy and outside the cell as a DAMP molecule. Recent research indicates that aberrant activation of HMGB1 signaling can promote the onset of inflammatory and autoimmune diseases, raising interest in the development of therapeutic strategies to control their function. The importance of HMGB1 activation in various forms of liver disease in relation to liver damage, steatosis, inflammation, fibrosis, tumorigenesis and regeneration is discussed in this review.

Notes

Acknowledgments

We apologize to the researchers who were not referenced because of space limitations. We thank Christine Heiner (Department of Surgery, University of Pittsburgh) for her critical reading of the manuscript. This work was supported by the National Institutes of Health (grant R01CA160417 to D Tang) and the National Natural Sciences Foundation of China (grant 81272253 to X-G Fan).

References

  1. 1.
    Goodwin GH, Sanders C, Johns EW. (1973) A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur. J. Biochem. 38:14–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Calogero S, et al. (1999) The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet. 22:276–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Andersson U, Tracey KJ. (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29:139–62.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Harris HE, Andersson U, Pisetsky DS. (2012) HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat. Rev. Rheumatol. 8:195–202.CrossRefPubMedGoogle Scholar
  5. 5.
    Kang R, Zhang Q, Zeh HJ 3rd, Lotze MT, Tang D. (2013) HMGB1 in cancer: good, bad, or both? Clin. Cancer Res. 19:4046–57.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Weir HM, et al. (1993) Structure of the HMG box motif in the B-domain of HMG1. EMBO J. 12:1311–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hardman CH, et al. (1995) Structure of the A-domain of HMG1 and its interaction with DNA as studied by heteronuclear three- and four-dimensional NMR spectroscopy. Biochemistry. 34:16596–607.CrossRefPubMedGoogle Scholar
  8. 8.
    Read CM, Cary PD, Crane-Robinson C, Driscoll PC, Norman DG. (1993) Solution structure of a DNA-binding domain from HMG1. Nucleic Acids Res. 21:3427–36.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Li J, et al. (2003) Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol. Med. 9:37–45.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yang H, et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U. S. A. 101:296–301.CrossRefGoogle Scholar
  11. 11.
    Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. (2002) Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 62:4805–11.PubMedGoogle Scholar
  12. 12.
    Yang HA, et al. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U. S. A. 107:11942–7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Venereau E, et al. (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209:1519–28.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Javaherian K, Liu JF, Wang JC. (1978) Nonhistone proteins HMG1 and HMG2 change the DNA helical structure. Science. 199:1345–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Wang H, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248–51.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Tang D, et al. (2010) HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 29:5299–310.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Yang H, et al. (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 18:250–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Hreggvidsdottir HS, et al. (2009) The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukoc. Biol. 86:655–62.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Wahamaa H, et al. (2011) High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res. Ther. 13:R136.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Tang D, et al. (2010) Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190:881–92.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Tang D, et al. (2011) High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab. 13:701–11.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Bonaldi T, et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22:5551–60.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Youn JH, Shin JS. (2006) Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J. Immunol. 177:7889–97.CrossRefPubMedGoogle Scholar
  24. 24.
    Gardella S, et al. (2002) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3:995–1001.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Vande Walle L, Kanneganti TD, Lamkanfi M. (2011) HMGB1 release by inflammasomes. Virulence. 2:162–5.CrossRefGoogle Scholar
  26. 26.
    Lu B, et al. (2012) Novel role of PKR in inflammasome activation and HMGB1 release. Nature. 488:670–4.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Scaffidi P, Misteli T, Bianchi ME. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–5.CrossRefGoogle Scholar
  28. 28.
    Kazama H, et al. (2008) Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity. 29:21–32.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Dupont N, et al. (2011) Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1beta. EMBO J. 30:4701–11.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Taguchi A, et al. (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 405:354–60.CrossRefGoogle Scholar
  31. 31.
    Palumbo R, et al. (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J. Cell Biol. 164:441–9.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Park JS, et al. (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 290:C917–24.CrossRefGoogle Scholar
  33. 33.
    Tian J, et al. (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8:487–96.CrossRefPubMedGoogle Scholar
  34. 34.
    Chen GY, Tang J, Zheng P, Liu Y. (2009) CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 323:1722–5.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Chiba S, et al. (2012) Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13:832–42.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Schiraldi M, et al. (2012) HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 209:551–63.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    van Golen RF, Reiniers MJ, Olthof PB, van Gulik TM, Heger M. (2013) Sterile inflammation in hepatic ischemia/reperfusion injury: present concepts and potential therapeutics. J. Gastroenterol. Hepatol. 28:394–400.CrossRefPubMedGoogle Scholar
  38. 38.
    Tsung A, et al. (2005) The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201:1135–43.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Watanabe T, et al. (2005) The role of HMGB-1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice. J. Surg. Res. 124:59–66.CrossRefPubMedGoogle Scholar
  40. 40.
    Nace GW, et al. (2013) Cellular-specific role of tolllike receptor 4 in hepatic ischemia-reperfusion injury in mice. Hepatology. 58:374–87.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Cai C, et al. (2013) CD14 contributes to warm hepatic ischemia-reperfusion injury in mice. Shock. 40:115–21.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Bamboat ZM, et al. (2010) Toll-like receptor 9 inhibition confers protection from liver ischemiareperfusion injury. Hepatology. 51:621–32.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Zeng S, et al. (2009) Receptor for advanced glycation end product (RAGE)-dependent modulation of early growth response-1 in hepatic ischemia/reperfusion injury. J. Hepatol. 50:929–36.CrossRefPubMedGoogle Scholar
  44. 44.
    Zhu P, et al. (2011) Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice. Hum. Gene Ther. 22:853–64.CrossRefPubMedGoogle Scholar
  45. 45.
    Evankovich J, et al. (2010) High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J. Biol. Chem. 285:39888–97.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Dhupar R, et al. (2011) Interferon regulatory factor 1 mediates acetylation and release of high mobility group box 1 from hepatocytes during murine liver ischemia-reperfusion injury. Shock. 35:293–301.CrossRefPubMedGoogle Scholar
  47. 47.
    Cardinal J, et al. (2009) Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury. Hepatology. 50:565–74.CrossRefPubMedGoogle Scholar
  48. 48.
    Ogiku M, Kono H, Hara M, Tsuchiya M, Fujii H. (2011) Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by Kupffer cells after ischemia-reperfusion in rats. J. Pharmacol. Exp. Ther. 339:93–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Li F, et al. (2013) The protective effect of PNU-282987, a selective alpha7 nicotinic acetylcholine receptor agonist, on the hepatic ischemiareperfusion injury is associated with the inhibition of high-mobility group box 1 protein expression and nuclear factor kappaB activation in mice. Shock. 39:197–203.CrossRefPubMedGoogle Scholar
  50. 50.
    Liu A, et al. (2013) The fibrin-derived peptide Bss15–42 attenuates the liver damage in a rat model of liver ischemia reperfusion injury. Shock. 2013, Feb 20 [Epub ahead of print].Google Scholar
  51. 51.
    Oishi K, et al. (2012) The vitamin E derivative, EPC-K1, suppresses inflammation during hepatic ischemia-reperfusion injury and exerts hepatoprotective effects in rats. J. Surg. Res. 176:164–70.CrossRefPubMedGoogle Scholar
  52. 52.
    Kang JW, Koh EJ, Lee SM. (2011) Melatonin protects liver against ischemia and reperfusion injury through inhibition of toll-like receptor signaling pathway. J. Pineal Res. 50:403–11.CrossRefPubMedGoogle Scholar
  53. 53.
    Izuishi K, et al. (2006) Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J. Immunol. 176:7154–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Shibayama Y, Asaka S, Nishijima A. (1991) Mechanism of liver injury following ischemia. Exp. Mol. Pathol. 55:251–60.CrossRefPubMedGoogle Scholar
  55. 55.
    Abu-Amara M, et al. (2010) Liver ischemia/reperfusion injury: processes in inflammatory networks: a review. Liver Transpl. 16:1016–32.CrossRefPubMedGoogle Scholar
  56. 56.
    Montalvo-Jave EE, Escalante-Tattersfield T, Ortega-Salgado JA, Pina E, Geller DA. (2008) Factors in the pathophysiology of the liver ischemia-reperfusion injury. J. Surg. Res. 147:153–9.CrossRefPubMedGoogle Scholar
  57. 57.
    Ilmakunnas M, et al. (2008) High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transpl. 14:1517–25.CrossRefPubMedGoogle Scholar
  58. 58.
    El-Serag HB, Rudolph KL. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–76.CrossRefGoogle Scholar
  59. 59.
    Arzumanyan A, Reis HM, Feitelson MA. (2013) Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat. Rev. Cancer. 13:123–35.CrossRefPubMedGoogle Scholar
  60. 60.
    Albayrak A, et al. (2010) Is HMGB1 a new indirect marker for revealing fibrosis in chronic hepatitis and a new therapeutic target in treatment? Viral Immunol. 23:633–8.CrossRefPubMedGoogle Scholar
  61. 61.
    Jung JH, et al. (2011) Hepatitis C virus infection is blocked by HMGB1 released from virus-infected cells. J. Virol. 85:9359–368.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Liu HB, et al. (2007) [Serum level of HMGB1 in patients with hepatitis B and its clinical significance.]. Zhonghua Gan Zang Bing Za Zhi 15:812–5.PubMedGoogle Scholar
  63. 63.
    Zhou RR, et al. (2011) HMGB1 cytoplasmic translocation in patients with acute liver failure. BMC Gastroenterol. 11:21.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Cheng BQ, et al. (2008) Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig. Liver Dis. 40:446–52.CrossRefPubMedGoogle Scholar
  65. 65.
    Wang LW, Chen H, Gong ZJ. (2010) High mobility group box-1 protein inhibits regulatory T cell immune activity in liver failure in patients with chronic hepatitis B. Hepatobiliary Pancreat. Dis. Int. 9:499–507.PubMedGoogle Scholar
  66. 66.
    Day CP, James OF. (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology. 114:842–5.CrossRefPubMedGoogle Scholar
  67. 67.
    Zuiderweg ER, et al. (2013) Allostery in the hsp70 chaperone proteins. Top. Curr. Chem. 328:99–153.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Li L, et al. (2011) Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology. 54:1620–30.CrossRefPubMedGoogle Scholar
  69. 69.
    Guo J, Friedman SL. (2007) Hepatic fibrogenesis. Semin. Liver Dis. 27:413–26.CrossRefPubMedGoogle Scholar
  70. 70.
    Kao YH, et al. (2008) High-mobility group box 1 protein activates hepatic stellate cells in vitro. Transplant. Proc. 40:2704–5.CrossRefPubMedGoogle Scholar
  71. 71.
    Ge WS, Wu JX, Fan JG, Wang YJ, Chen YW. (2011) Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells. World J. Gastroenterol. 17:4090–8.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Zhang Z, et al. (2012) High mobility group box 1 activates toll like receptor 4 signaling in hepatic stellate cells. Life Sci. 91:207–12.CrossRefPubMedGoogle Scholar
  73. 73.
    Wang FP, et al. (2013) High mobility group box-1 promotes the proliferation and migration of hepatic stellate cells via TLR4-dependent signal pathways of PI3K/Akt and JNK. PLoS One. 8:e64373.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Kostova N, Zlateva S, Ugrinova I, Pasheva E. (2010) The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol. Cell Biochem. 337:251–8.CrossRefPubMedGoogle Scholar
  75. 75.
    Liu F, et al. (2012) High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J. Transl. Med. 10:135.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Dong YD, et al. (2013) Expression and clinical significance of HMGB1 in human liver cancer: knockdown inhibits tumor growth and metastasis in vitro and in vivo. Oncol. Rep. 29:87–94.CrossRefPubMedGoogle Scholar
  77. 77.
    Jiang W, Wang Z, Li X, Fan X, Duan Y. (2012) High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Pathol. Oncol. Res. 18:293–8.CrossRefPubMedGoogle Scholar
  78. 78.
    Liang X, et al. (2009) Ethyl pyruvate administration inhibits hepatic tumor growth. J. Leukoc. Biol. 86:599–607.CrossRefPubMedGoogle Scholar
  79. 79.
    Yaser AM, et al. (2012) The role of receptor for advanced glycation end products (RAGE) in the proliferation of hepatocellular carcinoma. Int. J. Mol. Sci. 13:5982–97.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Yan W, et al. (2012) High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology. 55:1863–75.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Dapito DH, et al. (2012) Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 21:504–16.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Lee WM. (2004) Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology. 40:6–9.CrossRefPubMedGoogle Scholar
  83. 83.
    Antoine DJ, et al. (2012) Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J. Hepatol. 56:1070–9.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Antoine DJ, et al. (2013) Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology. 58:777–87.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Antoine DJ, Williams DP, Kipar A, Laverty H, Park BK. (2010) Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. Mol. Med. 16:479–90.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Wang H, Li W, Goldstein R, Tracey KJ, Sama AE. (2007) HMGB1 as a potential therapeutic target. Novartis Found. Symp. 280:73–85; discussion 85–91, 160–164.PubMedGoogle Scholar
  87. 87.
    Wang XF, Sun R, Wei HM, Tian ZG. (2013) High-mobility group box 1 (HMGB1)-toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: interaction of gamma delta T cells with macrophages. Hepatology. 57:373–84.CrossRefPubMedGoogle Scholar
  88. 88.
    Tang D, Billiar TR, Lotze MT. (2012) A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol. Med. 18:1360–2.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Antoine DJ, et al. (2012) Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J. Hepatol. 56:1070–9.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Antoine DJ, et al. (2009) High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol. Sci. 112:521–31.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Dragomir AC, Laskin JD, Laskin DL. (2011) Macrophage activation by factors released from acetaminophen-injured hepatocytes: potential role of HMGB1. Toxicol. Appl. Pharmacol. 253:170–77.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Yang R, et al. (2012) High mobility group B1 impairs hepatocyte regeneration in acetaminophen hepatotoxicity. BMC Gastroenterol. 12:45.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Gong QA, et al. (2010) High-mobility group box 1 exacerbates concanavalin A-induced hepatic injury in mice. J. Mol. Med. 88:1289–8.CrossRefPubMedGoogle Scholar
  94. 94.
    Zhou RR, et al. (2011) HMGB1 cytoplasmic translocation in patients with acute liver failure. BMC Gastroenterol. 11:21–31.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Taub R. (2004) Liver regeneration: from myth to mechanism. Nat. Rev. Mol. Cell. Biol. 5:836–47.CrossRefPubMedGoogle Scholar
  96. 96.
    Wang H, Zhu S, Zhou R, Li W, Sama AE. (2008) Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev. Mol. Med. 10:e32.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Szabo G, Mandrekar P, Dolganiuc A. (2007) Innate immune response and hepatic inflammation. Semin. Liver Dis. 27:339–50.CrossRefPubMedGoogle Scholar
  98. 98.
    Berasain C, et al. (2009) Inflammation and liver cancer: new molecular links. Ann. N. Y. Acad. Sci. 1155:206–21.CrossRefPubMedGoogle Scholar
  99. 99.
    Venereau E, et al. (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209:1519–28.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Yang H, et al. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U. S. A. 107:11942–7.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Abeyama K, et al. (2005) The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest. 115:1267–74.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Kim ID, et al. (2012) Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol. Ther. 20:829–39.CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Livesey K, et al. (2012) p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res. 72:1996–2005.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Yamamoto T, et al. (2010) Hemoperfusion with a high-mobility group box 1 adsorption column can prevent the occurrence of hepatic ischemia-reperfusion injury in rats. Crit. Care Med. 38:879–85.CrossRefPubMedGoogle Scholar
  105. 105.
    Xie K, et al. (2010) Protective effects of hydrogen gas on murine polymicrobial sepsis via reducing oxidative stress and HMGB1 release. Shock. 34:90–7.CrossRefPubMedGoogle Scholar
  106. 106.
    Tang D, et al. (2009) Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am. J. Respir. Cell Mol. Biol. 41:651–60.CrossRefPubMedPubMedCentralGoogle Scholar
  107. 107.
    Wang L, et al. (2010) Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kappaB expression. Neurosci. Lett. 471:152–6.CrossRefPubMedGoogle Scholar
  108. 108.
    Wang L, et al. (2010) Tanshinone II A down-regulates HMGB1, RAGE, TLR4, NF-kappaB expression, ameliorates BBB permeability and endothelial cell function, and protects rat brains against focal ischemia. Brain Res. 1321:143–51.CrossRefPubMedGoogle Scholar
  109. 109.
    Schierbeck H, Wahamaa H, Andersson U, Harris HE. (2010) Immunomodulatory drugs regulate HMGB1 release from activated human monocytes. Mol. Med. 16:343–51.CrossRefPubMedPubMedCentralGoogle Scholar
  110. 110.
    Yang M, et al. (2013) Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis. Biochem. Pharmacol. 86:410–8.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Ulloa L, et al. (2002) Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. U. S. A. 99:12351–6.CrossRefPubMedPubMedCentralGoogle Scholar
  112. 112.
    Mollica L, et al. (2007) Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem. Biol. 14:431–41.CrossRefPubMedGoogle Scholar
  113. 113.
    Chen G, et al. (2005) Suppression of HMGB1 release by stearoyl lysophosphatidylcholine: an additional mechanism for its therapeutic effects in experimental sepsis. J. Lipid Res. 46:623–7.CrossRefPubMedGoogle Scholar
  114. 114.
    Wang H, et al. (2006) The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. J. Nutr. 136:360–5.CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
    Li W, et al. (2007) A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J. Immunol. 178:3856–64.CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    Li W, et al. (2007) A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One. 2:e1153.CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    Li W, et al. (2011) EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. Biochem. Pharmacol. 81:1152–63.CrossRefPubMedPubMedCentralGoogle Scholar
  118. 118.
    Zhu S, et al. (2012) It is not just folklore: the aqueous extract of mung bean coat is protective against sepsis. Evid. Based Complement Alternat. Med. 2012:498467.PubMedPubMedCentralGoogle Scholar
  119. 119.
    Liliensiek B, et al. (2004) Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113:1641–50.CrossRefPubMedPubMedCentralGoogle Scholar
  120. 120.
    Hagiwara S, Iwasaka H, Hasegawa A, Koga H, Noguchi T. (2008) Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit. Care Med. 36:2407–13.CrossRefPubMedGoogle Scholar
  121. 121.
    Wang H, et al. (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10:1216–21.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2013

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of PittsburghPittsburghUSA
  2. 2.Department of Infectious Diseases and State Key Lab of Viral Hepatitis, Xiangya HospitalCentral South UniversityChangsha, HunanChina
  3. 3.Hillman Cancer CenterPittsburghUSA

Personalised recommendations